ORIGINAL ARTICLE

High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC)

B Sonnweber¹, M Dlaska¹, S Skvortsov¹, S Dirnhofer², T Schmid³ and W Hilbe¹

¹ Department of Internal Medicine, Division of General Internal Medicine, Medical University Innsbruck, Austria
² Institute of Pathology, Medical University Innsbruck, Austria and University of Basel, Basel, Switzerland
³ Department of Surgery, Medical University Innsbruck, Austria

Correspondence to:
Correspondence to:
Dr W Hilbe
Division of General Internal Medicine, Medical University Innsbruck, Anichstraße 35, A-6020 Innsbruck, Austria; wolfgang.hilbe{at}uibk.ac.at

Aims: Overexpression and mutation of epidermal growth factor regulator (EGFR) are frequently found in the carcinogenesis of non-small cell lung cancer (NSCLC). Because targeting of this receptor has proven therapeutic efficacy, studying EGFR has become a matter of particular scientific interest. The present study analysed the EGFR receptor, rate of EGFRvIII mutations, and rate of activated phosphorylated EGFR (pEGFR) by immunohistochemistry on cryostat sections.

Methods: Surgically obtained tumour specimens of a series of 78 NSCLC patients and 66 adjacent tumour free specimens were examined immunohistochemically using monoclonal antibodies to stain EGFR, pEGFR, and EGFRvIII.

Results: EGFRvIII and pEGFR expression was found in 42% and 26% of the tumours respectively and both were increased significantly compared with tumour free samples. EGFR, pEGFR, and EGFRvIII expression did not correlate with any of the previously tested markers (c-erbB-2, c-erbB-3, p53, ki-67, and microvessel density). Similar distributions of immunohistochemical profiles were seen, regardless of histological subtype, age, or sex. In stage I patients, EGFR phosphorylation at tyrosine residue 845 proved to be an independent prognostic factor.

Conclusion: Because pEGFR correlated with poor prognosis, it can be speculated that it plays a crucial biological role in the pathogenesis of NSCLC.

Abbreviations: EGFR, epidermal growth factor regulator; MVD, microvessel density; NSCLC, non-small cell lung cancer; pEGFR, phosphorylated epidermal growth factor regulator; SCC, squamous cell carcinoma

Keywords: EGFR; EGFRvIII; phosphorylation; non-small cell lung cancer; prognosis

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Schittenhelm, M. M., Kollmannsberger, C., Oechsle, K., Harlow, A., Morich, J., Honecker, F., Kurek, R., Storkel, S., Kanz, L., Corless, C. L., Wong, K.-K., Bokemeyer, C., Heinrich, M. C. (2009). Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. Molecular Cancer Therapeutics 8: 481-489 [Abstract] [Full Text]  
• West, C M, Joseph, L, Bhana, S (2008). Epidermal growth factor receptor-targeted therapy. Br. J. Radiol. 81: S36-S44 [Abstract] [Full Text]